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Animals undergo substantial changes in many physiologic and biochemical functions as a natural consequence of aging. In the absence of disease
or other pathologic conditions, these changes occur in a gradual manner with time (generally expressed as a fractional or percentage change in that
function per year or decade). Furthermore, for any given function and at any given chronologic age, there is large variation in that function among
individuals. Given the increase in life expectancy, the substantial increase in the number of elderly (and aged elderly) in the population, and the esca-
lating costs of health care, there is great interest in learning more about the risks associated with aging as a result of toxic exposure. Are the elderly
at greater risk than younger adults to the toxic effects of drugs and environmental exposure? Is the elderly population an inherently more sensitive
one? - Environ Health Perspect 102(Suppl 11):1 19-124 (1994)
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Introduction
This brief review will examine the changes
with age in the processes ofdisposition that
drugs and toxic agents undergo in the
body: absorption, distribution, excretion,
and metabolism. Gastrointestinal absorp-
tion appears to be unimpaired with age in
terms of the completeness of absorption
(rate is often reduced), with the possible
exception of those compounds having a
high hepatic extraction ratio (i.e., high
hepatic clearance). Absorption by other
routes, including pulmonary and dermal,
has not been well studied. Distribution
may be altered, depending upon the chem-
ical characteristics of the compound, as a
result of reduced plasma protein binding
(in response to a decrease in plasma albu-
min concentrations) and anatomical
changes (especially an increase in the per-
centage body weight that is fat and a
decrease in the lean mass). Renal function
declines with age, which affects the clear-
ance and elimination half-life of renally
excreted compounds (and their metabo-
lites). Hepatic clearance either decreases or
remains unchanged but it is difficult to
make any general rules because metabolism
is affected by numerous factors. It appears
that phase I processes are more affected by
age than phase II reactions.
In recent years, there has been consid-
erable interest in understanding how aging
in humans may influence the disposition of
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and the response to drugs and toxic agents.
In addition to having recognized that age is
a variable that may alter drug response and
disposition in laboratory animals and,
therefore, an analogous situation probably
would exist among humans, the current
interest in aging is driven by several factors.
These considerations make the elderly a
unique group within the population.
Considerations involving the elderly, in
comparison to younger adults, include the
increasing percentage of elderly people
as well as the aged elderly (those over
75 years) in the population (the "baby-
boomers" have now reached middle age); a
greater incidence ofdisease and physiologi-
cal impairments; occupation of a greater
percentage ofhospital beds and long-term
care facilities; greater drug ingestion per
capita; and greater incidence of adverse
drug effects and drug-drug interactions.
While there has been a substantial
increase in the quality and quantity of the
gerontology literature during the past
decade, unanswered questions and numer-
ous conflicting reports remain. The early
literature particularly suffers from inade-
quate controls, poor experimental design,
and insufficient methods of data analysis.
Nowhere is this more apparent than in the
pharmacokinetics literature in gerontology.
These issues as well as a review ofdrug dis-
position in the elderly have been discussed
elsewhere (1). It would be useful to keep in
mind several of these concerns. For exam-
ple, chronological age per se, while it is the
only definition ofage currently available, is
a poor and variable predictor of biological
activity (or function). Furthermore, what
age defines elderly? Very often 65 years is
used for such a demarcation, but this
would appear to be artificial and without
justification. Most studies are designed to
be cross-sectional rather than longitudinal;
while the former provides results allowing
conclusions about differences between
ages, the latter gives more useful informa-
tion about changes with age.
Figure 1, which is a plot ofthe percent-
age function remaining versus adult age,
indicates a particularly important concept,
body functions decline gradually at a rela-
tively constant rate over time. This contin-
uum tends to illustrate the uselessness ofan
arbitrary age to delimit young from elderly
(1,2). The following discussion will
attempt to summarize our current under-
standing of how aging influences the
processes ofdrug disposition.
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Figure 1. Percentage of function remaining versus
age. The values shown are relative to those at age 30
years. (e) Maximal breathing capacity; (w-) renal
plasma flow by para-amino hippurate clearance; (o)
renal plasma flow by diodrast clearance; (A) vital
capacity; (m) glomerular filtration rate by inulin clear-
ance; (A) cardiac index. From Mayersohn (1) and Rowe
and Besdine (2); reprinted with permission.
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There is little information concerning
the relationship between age and intestinal
transit rates. The latter may be important
in that prolonged residence in the intestinal
tract might promote dissolution and
absorption, whereas rapid transit would
have the opposite effect. The general
impression is that aging is associated with
reduced gastrointestinal muscle tone and,
therefore, decreased intestinal motility and
perhaps prolonged transit times. However,
one study suggests no difference in small
intestinal transit times between an elderly
group and a group ofyoung subjects (10).
The gastrointestinal tract is well per-
fused by blood flow, which is consistent
with absorption being one of its major
functions. Normally, except for com-
pounds with extremely high permeability
coefficients, blood flow does not appear to
rate-limit absorption. There is a reduction
in splanchnic blood flow with aging (11)
that might, under certain exacerbating cir-
cumstances (e.g., congestive heart failure),
become the rate-limiting step in absorp-
tion. The reduced blood flow may decrease
absorption rate in general.
The mucosal surface area appears to be
reduced by about 20%, as determined in a
group ofelderly (60-73 years) compared to
younger adults (16-30 years) (12). This
decrease in surface area, unless there is a
compensating increase in membrane per-
meability, would imply a reduction in
absorption rate. Indeed, alterations ofsev-
eral of the factors noted above in the
elderly (i.e., gastric emptying, intestinal
transit, blood flow, surface area) would
suggest a decrease in absorption rate. A
review of the relevant literature supports
that suggestion (1). As a general conclu-
sion, the completeness ofgastrointestinal
absorption is unaltered with aging, but
there is often a reduction in the rate of
absorption.
The only exception to the general rule
of unaltered completeness ofabsorption in
the elderly is a group ofcompounds whose
systemic absorption may increase with
aging. Compounds with a high hepatic
clearance (or high extraction ratio) undergo
extensive hepatic first-pass metabolism and,
if hepatic clearance declines with age, the
absorption ofthe parent compound will be
greater in the elderly adults compared to
younger adults. There are now several drug
examples to support this suggestion (e.g.,
L-DOPA, chlormethiazole, propranolol,
lidocaine, nalbuphine) (13).
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Unfortunately, little can be said about
the influence ofaging on the extent or rate
of absorption across other membranes
associated with different routes ofadminis-
tration (e.g., intramuscular, subcutaneous,
rectal, pulmonary, dermal). One recent
study indicates lower dermal penetration of
hydrophilic compounds in the aged human
skin but no age relationship for two lipid-
soluble compounds (14). In terms ofdrug
dosing and environmental exposure, these
are relevant routes that require further
study to determine the relationship
between aging and absorption.
Distribution
One needs to consider a variety of factors
whose alteration with aging may have an
impact upon the rate and extent to which a
molecule distributes throughout the body.
The major considerations include plasma
protein concentration, body composition,
blood flow, tissue-protein concentration,
and fluid pH. Alterations in any of these
factors will often express themselves in the
value of the apparent volume ofdistribu-
tion of the compound or the apparent
space that it occupies relative to blood con-
centration.
Alterations in plasma protein binding
are particularly important because,
depending upon the characteristics of the
compound, such changes may modify the
values ofclearance and apparent volume of
distribution and elimination half-life (1).
Furthermore, such changes may alter the
resulting steady-state unbound and bound
blood concentrations that, in turn, affect
the magnitude of response (1). Albumin,
which is the major drug-binding protein in
serum, decreases in concentration with age,
and this decrease becomes more apparent
during illness (15-17). An alteration in
binding in the absence of a reduction in
serum albumin concentration would indi-
cate that factors other than protein concen-
tration are involved. A likely possibility
would be the presence ofother drugs being
ingested or the presence of metabolites of
the drug that compete for binding (18).
The role of such additional complicating
factors that affect binding might not be
recognized by determining binding in
spiked blank plasma. This is in contrast to
the determination of binding using
authentic plasma samples (i.e., plasma
from a subject ingesting the drug). In
reviewing the literature about the relation-
ship between plasma protein binding of
drugs and age, one notes frequent inconsis-
tencies and contradictions. Furthermore,
the correlation coefficients for such rela-
tionships are low (1). In general, plasma
protein binding (usually involving albu-
min) either decreases or remains
unchanged as a function ofage. A possible
exception to this rule is binding of basic
compounds to the acute phase protein, ax-
acid glycoprotein, whose concentrations
may rise in response to a variety ofdiseases
and disorders prevalent in the elderly and,
in turn, may increase the degree of drug
binding (e.g., propranolol) (19,20). It is
not clear whether concentrations of this
protein increase as a natural consequence
of aging because the results of one study
have shown no such age relationship in 68
normal subjects (21).
In contrast to plasma protein binding,
we know far less about tissue binding
processes and how they may change in
response to age and other factors. The rea-
son for this is the experimental difficulty in
measuring tissue binding in vitro without
disrupting the integrity ofthe tissue and its
protein content. There may be reason to
suggest decreased tissue binding in the
aged as a result ofreduced tissue mass and
protein loss; however, there is little ifany
direct evidence to support that contention.
Often, changes in tissue protein binding of
a drug (actually a compartmental tissue or
region in an abstract pharmacokinetic
model) is inferred from the analysis of
plasma concentration-time data. For exam-
ple, ifthere is a change in the apparent vol-
ume of distribution of the compound in
the absence of a change in plasma protein
binding, one is tempted to conclude that
there has been a change in tissue binding
of the drug. Such is the case for the car-
dioactive drug, digoxin, whose reduced
apparent volume of distribution and
myocardium/ serum concentration ratio in
the presence of impaired renal function
appears to reflect reduced muscle tissue
binding ofthe drug (22).
A second major factor contributing to
an age-dependent alteration in distribution
is the change in body composition whose
affect on distribution will in turn be a
function ofthe physicochemical character-
istic of the drug. This change in terms of
lean body mass and fat for both females
and males is shown in Figure 3. When
expressed as a percentage ofbody weight,
lean mass decreases while fat mass increases
with age for both genders. This change
results in an age-dependent decrease in the
apparent volume of distribution for a
water-soluble compound such as ethanol
(23) and an increase in volume for a lipid-
soluble drug such as thiopental (24). The
latter relationship is illustrated in Figure 4.
cm
._
10
0
(a 100
BC
60
40
20
25 45 55 65-70
Age, years
Figure 3. Percentage of body weight in males (bot-
tom) and females (top) as a function of age and
expressed as lean body mass and fat. The numbers
above the bar graphs are the number of subjects. From
Mayersohn (1); reprinted with permission.
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Figure 4. Relationship between the apparent volume
of distribution (Vp) and the steady-state volume of dis-
tribution(V., shown in the inset) of thiopental and age
in 22 lean female subjects undergoing surgery. The
solid lines represent linear regression analysis of the
data: Vo, r=0.64, p<0.001; VSS, r=0.70, p<0.001.
From Jung et al. (24); reprinted with permission.
Therefore, the direction of change of the
apparent volume of distribution is a func-
tion of the solubility characteristics of the
compound. Assuming there is no change
in plasma protein binding, water-soluble
compounds would be expected to show a
decrease in the apparent volume, while
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Figure 5. Various parameters of renal function versus average age in males. (A) Inulin clearance (@). (B) Tubular
excretory capacity expressed as the transport maximum (Tm) of iodopyracet (Diodrast) (U). (C) Renal blood flow
(A). (D) Renal plasma flow as measured by Diodrast clearance (o). (E) The values in A through Dexpressed as a
percentage of the value of the youngest age group (20-29 years). The cross-hatched vertical bars represent the
standard deviation, and the numbers above the bars in A are the number of subjects in each age group. From
Mayersohn (29) and Davies and Shock (30); reprinted with permission.
lipid-soluble compounds would be
expected to evidence an increase in volume.
In reviewing the relationship between
apparent volume and age for any given
compound, only poor correlation co-
efficients were noted (1).
Cardiac output and cardiac index are
known to decline substantially with age, and
there is large variability among subjects in
the degree ofthat change (25). In contrast
to this conclusion, a more recent study indi-
cates that there is no relationship between
cardiac output and age when subjects with
no evidence ofcoronary artery disease are
selected for study; however, large variation
among subjects at any given age remains
(26). Therefore, age per se may not be asso-
ciated with a decline in cardiac output. Any
changes in blood flow that occur are not
uniform throughout the body; cerebral flow
declines at a slower rate with age in compar-
ison with flow to the liver and kidney. This
decrease in flow needs to be considered in
relation to the organ or tissue weight, which
may also decline with age. As a result, the
effective flowper tissue weight may not
decrease to an extent suggested by the
absolute value offlow.
Reduced blood flow to eliminating
organs may be important for those com-
pounds that have a high clearance or
extraction ratio (compounds that are non-
restrictively cleared) because the elimina-
tion of such compounds depends upon
blood flow. Furthermore, assuming there is
no change in distribution, the reduced
clearance ofsuch compounds will produce
an increase in half-life as a result of
decreased blood flow. Altered blood flow to
sites of action may result in an increase in
the onset time for a response to be initiated.
Renal Excretion
Renal excretion ofdrugs (and metabolites)
into the urine represents one of the major
routes ofelimination, in addition to hepatic
metabolism. The influence of aging on
renal function has been thoroughly studied.
While there is considerable variation at any
given age, all aspects of renal function
appear to decline with age. In contrast to
hepatic metabolism, one can accurately
assess various aspects ofkidney function
such as glomerular filtration rate with mea-
surements such as creatinine or inulin clear-
ance. Processes of active secretion and
reabsorption may also be accurately esti-
mated. Quantitative relationships between
drug elimination (usually measured as clear-
ance or elimination rate constant) and crea-
tinine clearance have been developed for
many drugs, and they serve an important
clinical function in being able to adjust a
dosing regimen for renal impairment.
Creatinine clearance is the most fre-
quently used index ofglomerular filtration
rate, primarily because creatinine is an
endogenous material that makes it unnec-
essary to administer an exogenous com-
pound. The measurement involves
determination of urinary creatinine excre-
tion (often during 24 hr) and a serum crea-
tinine concentration. Interestingly, while
creatinine excretion decreases with age,
there is little change in serum creatinine
concentration. The steady-state serum crea-
tinine concentration (SCR) may be written
as a function offormation and elimination,
SCR = production rate/CLCR' where produc-
tion rate represents formation and creati-
nine clearance (CLCR) represents
elimination. For SCR to remain constant
while CLCR decreases with age, the produc-
tion rate must be decreasing parallel to
clearance. The latter is consistent with the
biochemistry ofcreatinine, which is an end
product of muscle metabolism. Because
there is a reduction in muscle mass with
aging, it is reasonable to expect that the
production of creatinine will also decline.
One important aspect ofthis relationship is
that one cannot evaluate renal function
across ages by measurement ofserum crea-
tinine concentration only, in the absence of
any kidney disease. However, since SCR is
often a measured blood biochemistry value,
it would be useful to be able to relate that
value to creatinine clearance. One such
relationship that incorporates several vari-
ables (body build or weight, age, gender) is
given by (27)
CLCR (ml/min) =
[ideal weight, kg] [140-age, yr]
72 x SCR(mg%)
The above relationship needs to be multi-
plied by 0.86 for females (as a result of a
smaller muscle mass).
As the kidney ages, it undergoes
anatomic and physiologic changes, includ-
ing a decrease in mass and a reduction in
the number and size ofthe nephrons (28).
These changes are reflected in virtually all
aspects of renal function, as shown in
Figure 5 (29,30). It is particularly interest-
ing to note that these various measures
with age almost superimpose when they are
expressed as a percentage of the youngest
age group. This observation has been
expressed as the intact nephron concept,
which states that all aspects ofkidney func-
tion decline uniformly. Therefore, as a gen-
eral rule, renal clearance of compounds
excreted by the kidneywill decline with age
and the elimination half-life will increase
with age.
HepaticMetabolism
Hepatic metabolism and its relationship
with aging is the most difficult ofall ofthe
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dispositional processes to discuss and reach
general conclusions. There are at least two
major reasons for this difficulty. First,
unlike renal function, there is no measure-
ment that is quantitatively related to and
would allow us to assess hepatic metabolic
function. Second, again unlike renal func-
tion, there are a host of factors that con-
tribute to the enormous variability in
hepatic function among subjects (i.e., fac-
tors that affect intrinsic enzymatic activity).
The latter is true even within a normal,
healthy, well-defined population of sub-
jects of similar ages. Consider variability
expected as a result ofthe following factors:
blood flow, concurrent drug use (induding
alcohol, drugs ofabuse, and caffeine), dis-
ease or physiologic disorders, environmen-
tal exposure (including smoking), gender,
genetic differences, liver mass, nutritional
intake, and physical condition. As a result,
it is not surprising that it is extremely
difficult to factor out age as a separate vari-
able among the host of other considera-
tions. To do so would require extreme care
in the selection of subjects, the design of
the study, and controlling as many vari-
ables as possible.
In a manner similar to the kidney, the
liver undergoes a number ofchanges with
age that includes a reduction in blood flow
(31) and mass (or volume) (32,33). Re-
duced blood flow might suggest a reduc-
tion in the clearance of those compounds
with a high hepatic clearance (or high
extraction ratio, nonrestrictively cleared). It
is more difficult to interpret the changes in
liver mass. Several studies have shown a
direct correlation between liver mass and
clearance ofcompounds with a low clear-
ance and that undergo oxidative metabo-
lism (antipyrine and phenytoin) (33,34).
The correlation coefficients, however, are
quite low and would not be considered
predictive. (The coefficients ofdetermina-
tion generally are less than 0.5.)
Several observations need to be made at
this juncture. First, there are conflicting
results in the literature with regard to the
relationship between age and estimates of
metabolic efficiency for any given com-
pound. This, in part, is a result ofthe use
ofvery different populations ofsubjects,
especially elderly subjects (e.g., with regard
to health status and concurrent drug use).
Confusion about the relative merits of
clearance and elimination half-life in
assessing metabolic activity remains. While
the latter is a very useful parameter, it is
not useful in the context of comparing
metabolic efficiency ofa given compound;
clearance is the preferred parameter. The
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Figure 6. Antipyrine clearance as a function of age in 307 healthy male subjects (18-92 years). Equation of the
line is Y=-0.19X + 40.7 (r=-0.249, p<0.001). From Vestal et al. (36); reprinted with permission.
reason for this is the fact that half-life is a
parameter dependent on clearance and vol-
ume ofdistribution. Thus, a difference in
the half-life between two populations could
be the result ofdifferences in distribution
volume as easily as it could be differences
in clearance. In fact, this has been observed
for several compounds (e.g., thiopental and
diazepam) (24,35). Therefore, clearance,
which is not dependent upon distribution
volume but is'a measure of the organ's
ability to eliminate the compound, is the
preferred parameter for measurement of
metabolic efficiency and for comparing dif-
ferent populations. Because differences in
plasma protein binding can affect the value
ofclearance, the ideal clearance parameter
would be the one corrected for binding
(i.e., unbound clearance). Unfortunately,
the latter is seldom measured or reported
in the literature.
The data illustrated in Figure 6 (36)
indicate the challenge facing investigators
who attempt to assess the relationship
between age and hepatic metabolism. The
most remarkable aspect of the data is the
magnitude of the variation in antipyrine
clearance at any given age. After reviewing
the relationship between age and hepatic
metabolism (37), the only general conclu-
sion that may be made is that hepatic
metabolism of compounds undergoing
phase I metabolism is either reduced or
unaltered. There are virtually no examples
of increased clearance with age.
Furthermore, while not thoroughly stud-
ied, the general impression is that com-
pounds undergoing phase II (conjugation)
processes are not as affected by age. Further
complicating this situation is the recent
indication that there may be age-depen-
dent differences in the enantiomeric
metabolism of certain compounds. One
example is the metabolism of the enan-
tiomers ofhexobarbital (38). Elderly male
subjects had a lower oral clearance for the
1-isomer in comparison to the value in
younger adults, whereas there were no dif-
ferences in the oral clearances ofthe d-iso-
mer. This area has received little attention,
but now there is great interest in studying
the disposition ofenantiomers because we
now have the ability to separate enan-
tiomers and perform quantitative analyses
easily.
An additional issue that has not been
thoroughly addressed is the possibility of
age-related differences in metabolism as a
function ofgender. Another question that
has not been examined rigorously is the
relative enzymatic induction and inhibition
ability as a function ofage. Are the elderly
more or less prone to enzymatic alteration
than the younger adult?
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